Butanol Fraction of Olax Subscorpioidea Produces Antidepressant Effect: Evidence for the Involvement of Monoaminergic Neurotransmission

Abstract

This study sought to investigate involvement of monoaminergic mechanism in the antidepressant action of butanol fraction (BF) of Olax subscorpioidea in rodents and the bioactive principles present. Butanol fraction was evaluated for antidepressant-like effect in the tail suspension, forced swimming and open field tests. All animals were treated with BF (5, 10 & 20 mg/kg) thirty minutes prior to the tests. On the other hand, monoaminergic neurotransmission involvement was probed by pre-treating animals with yohimbine hydrochloride (1 mg/kg, α₂ antagonist), prazosin (62.5 µg/kg, α₁ antagonist), propranolol (2 mg/kg, non-selective β antagonist), sulpiride (50 mg/kg, D₂ receptor blocker), haloperidol (0.2 mg/kg, non-selective D receptor blocker), metergoline (4 mg/kg, i.p., a 5HT-receptor blocker) and PCPA (100 mg/kg, i.p., inhibitor of tryptophan hydroxylase), fifteen minute before treatment with BF (10 mg/kg). Identification of the major bioactive constituents was done by HPLC. The findings show that BF (5 & 10 mg/kg) significantly decreased immobility in despair tests of depression without effect on locomotor activity. The data also shows that anti-immobility effect of BF (10 mg/kg) in the TST was reversed by prazosin, yohimbine, haloperidol, sulpiride, metagoline and PCPA but not with propranolol. Bioactive principles present are caffeic acid, rutin, morin and quercetin. In conclusion, our findings show that BF produces antidepressant-like effect, which may be dependent on its interaction with the monoaminergic system.

Key words

Olax subscorpioidea - Olacecae - monoaminergic transmission - depression

• References

• 1 WHO. Mental health: Facing the challenges, building solutions. Report from the WHO European Ministerial Conference. Copenhagen, Denmark: WHO Regional Office for Europe; 2005
• 2 Elhwuegi AS. Central monoamines and their role in major depression. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2004; 28: 435-451
• 3 Papakostas GI. Dopaminergic-based pharmacotherapies for depression. Eur Neuropsychopharmacology 2006; 16: 391-402
• 4 Ibrahim JA, Muazzam I, Jegede IA. et al. Ethno-medicinal plants and methods used by Gwandara tribe of Sabo Wuse in Niger state, Nigeria, to treat mental illness. African Journal of Traditional, Complementary and Alternative Medicines 2007; 4: 211-218
• 5 Victoria UC, Micheal UC, Johnny MU. Evaluation of the antiulcer activity of Olax subscorpioidea Oliv. Roots in rats. Asian Pacific Journal of Tropical Medicine 2010; 3: 13-16
• 6 Bouquet A.Féticheurs et médecines traditionnelles du Congo (Brazzaville). Mém. O.R.S.T.O.M., http://www.docstoc.com/docs/41737230/Ficheurs-et-mecines-tradition 1969; 36: 282
• 7 Sonibare MA, Gbile ZO. Ethnobotanical survey of anti-asthmatic plants in south western Nigeria. Afr. J. Trad. CAM 5 2008; 4: 340-345
• 8 Mike OS, Amusa NA, Raji-Esan SO. et al. Ethnobotanical Survey of Anti-Cancer Plants in Ogun State, Nigeria. Annals of Biological Research 2010; 1: 261-273
• 9 Soladoye MO, Amusa NA, Raji-Esan SO. et al. Ethnobotanical survey of anti-cancer plants in Ogun state, Nigeria. Ann Biol Res 2010; 1: 261-273
• 10 Adjanohoun EV, Adjakidje MRA, Ahyi K et al. Contribution aux études ethnobotaniques et floristiques au Togo. Agence de coopération culturelle et technique, (A.C.C.T.), Paris, 671 p., From the data bank PHARMEL 2 (ref. HP 10) 1986;
• 11 Ayandele AA, Adebiyi AO. The phytochemical analysis and antimicrobial screening of extracts of Olax subscorpioidea. African Journal of Biotechnology 2007; 6: 868-870
• 12 Adeoluwa OA, Aderibigbe AO, Olonode ET. Antinociceptive property of ethanol leaf extract of Olax subscorpioidea. Journal of Ethnopharmacology 2014; 156: 353-357
• 13 Ishola IO, Akinyede A, Lawal SW. et al. Antinociceptive and anti-inflammatory effects of Olax subscorpioidea Oliv. (Olacaceae) leaf extract in rodents: Possible mechanisms of antinociceptive action. West African Journal of Pharmacy 2015; 26: 99-112
• 14 Adeoluwa OA, Aderibigbe AO, Bakre AG. Evaluation of antidepressant-like effect of Olax subscorpioidea Oliv. (Olacaceae) extract in mice. Drug Research 2015; 65: 306-311
• 15 Adeoluwa OA, Aderibigbe AO, Agu AG. Pharmacological evaluation of central nervous system effects of ethanol leaf extract of Olax subscorpioidea in experimental animals. Drug Research 2016; 65: 1-7
• 16 Kazeem MI, Ayeleso OA, Mukwevho E. Olax subscorpioidea Oliv. Leaf alleviates postprandial hyperglycaemia by inhibition of alpha-amylase and alpha-glucosidase. International journal of Pharmacology 2015; 11: 484-489
• 17 Adegbite OS, Akinsaya YI, Kukoyi AJ. et al. Induction of rat hepatic mitochondrial membrane permeability transition pore opening by leaf extract of Olax subscorpioidea. Pharmacognosy Research 2015; 7: S63-S68
• 18 Porsolt RD. Behavioural Despair, in antidepressants: Neurochemical, behavioural and clinical perspectives. Eds. by Enna SJ, Malick JB, Richelson E. New York: Raven Press; 1981: 121-139
• 19 Porsolt RD, Anton G, Blavet N. et al. Behavioral despair in rats. A new animal model sensitive to antidepressive treatments. Eur J Pharmacol. 1978; 47: 379-391
• 20 Cryan JF, Mombereau C, Vassout A. The tail suspension test as a model for assessing antidepressant activity: Review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev. 2005; 29: 571- 625
• 21 Thierry B, Steru L, Simon P. et al. The tail suspension test: Ethical considerations. Psychopharmacology 1986; 90: 284-285
• 22 Renard CE, Dailly E, David DJ. et al. Monoamine metabolism changes following the mouse forced swimming test but not the tail suspension test. Fundam Clin Pharmacology 2003; 17: 449 - 455
• 23 Schildkraut JJ. The catecholamine hypothesis of affective disorders: A review of supporting evidence. Am J Psychiatry 1965; 122: 509-522
• 24 Duman RS, Henninger GR, Nestler EJ. A molecular and cellular theory of depression. Archives of General Psychiatry 1997; 54: 597- 606
• 25 Wong MA, Licinio J. Research and treatments approaches to depression. Nature neuroscience 2001; 2: 343-351
• 26 Wang YM, Xu F, Gainetdinov RR. et al. Genetic approaches to studying norepinephrine function: Knockout of the mouse norepinephrine transporter gene. Biol Psychiatry 1999; 46: 1124-1130
• 27 Brunello N, Blier P, Judd LL. et al. Noradrenaline in mood and anxiety disorders: Basic and clinical studies. International clinical psychopharmacology 2003; 18: 191-202
• 28 Dziedzicka-Wasylewska M, Faron-Górecka A, Kuśmider M. et al. Effect of antidepressant drugs in mice lacking the norepinephrine transporter. Neuropsychopharmacology 2006; 31: 2424-2432
• 29 Danysz W, Kostowski W, Kozak W. et al. On the role of noradrenergic neurotransmission in the action of desipramine and amitriptyline in animal models of depression. Pol. J. Pharmacol. Pharm. 1998; 38: 285-298
• 30 Masuda Y, Ohnuma S, Sugiyama T. α 2-adrenoceptor activity induces the antidepressant-like glycolipid in mouse forced swimming. Methods Find Exp Clin Pharmacol. 2001; 23: 19 -21
• 31 Stone EA, Grunewald GL, Lin Y. et al. Role of epinephrine stimulation of CNS α 1-adrenoceptors in motor activity in mice. Synapse 2003; 4 9: 67-76
• 32 Flugge G, Van Kampen M, Meyer H. et al. α2A and α2C-adrenoceptor regulation in the brain: α2A changes persist after chronic stress. European Journal of Neuroscience 2003; 17: 917-928
• 33 Ordway GA, Schenk J, Stockmeier CA. et al. Elevated agonist binding to α 2-adrenoceptors in the locus coeruleus in major depression. Biological psychiatry 2003; 53: 315-323
• 34 Kitada Y, Miyauchi T, Kanazawa Y. et al. Involvement of α- and β 1-adrenergic mechanisms in the immobility-reducing action of desipramine in the forced swimming test. Neuropharmacology 1983; 22: 1055- 1060
• 35 Millan MJ. The role of monoamines in the actions of established and “novel” antidepressant agents: A critical review. Eur J Pharmacol 2004; 500: 371-384
• 36 D'Aquila PS, Collu M, Gessa GL. et al. The role of dopamine in the mechanism of action of antidepressant drugs. Eur J Pharmacol 2000; 405: 365 -373
• 37 Willner P, Hale AS, Argyropoulos S. Dopaminergic mechanism of antidepressant action in depressed patients. J Affect Dis 2005; 86: 37 - 45
• 38 Waehrens J, Gerlach J. Bromocriptine and imipramine in endogenous depression. A double-blind controlled trial in out-patients. J Affect Disord 1981; 3: 193 -202
• 39 Dailly E, Chenu F, Renard CE. et al. Dopamine, depression and antidepressants. Fundam Clin Pharmacol. 2004; 6: 601-607
• 40 Yamada J, Sugimoto Y, Yamada S. Involvement of dopamine receptors in the anti-immobility effects of dopamine re-uptake inhibitors in the forced swimming test. Eur J Pharmacol 2004; 504: 207 - 211
• 41 Teste JF, Martin I, Rinjard P. Electrotherapy in mice: Dopaminergic and noradrenergic effects in the Tail Suspension Test. Fundam Clin Pharmacol 1990; 4: 39-47
• 42 Ansorge MS, Hen R, Gingrich JA. Neurodevelopmental origins of depressive disorders. Curr Opin Pharmacol 2007; 53: 8-17
• 43 Montgomery SA. Predicting response: noradrenaline reuptake inhibition. International Clinical Psychopharmacology 1999; 14: 21-26
• 44 Taylor S, Stein MB. The future of selective serotonin reuptake inhibitors (SSRIs) in psychiatric treatment. Medical Hypotheses 2006; 66: 14-21
• 45 Kreiss DS, Lucki I. Effects of acute and repeated administration of antidepressant drugs on extracellular levels of 5-hydroxytryptamine measured in vivo. J Pharmacol. Exp Ther 1995; 274: 866 -876
• 46 Blier P, Ward NM. Is there a role for 5-HT1A agonists in the treatment of depression?. Biological Psychiatry 2003; 53: 193 -203
• 47 Carvalho AF, Machado JR, Cavalcante JL. Augmentation strategies for treatment-resistant depression. Curr Opin Psychiatry 2008; 22: 7-12
• 48 Shelton RC, Tollefson GD, Tohen M. et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001; 158: 131-134
• 49 Diaz SL, Doly S, Narboux-Neme N. et al. 5-HT2B receptors are required for serotonin-selective antidepressant actions. Mol Psychiatry 2012; 17: 154-163
• 50 Cryan JF, Lucki I. Antidepressant-like behavioral effects mediated by 5-hydroxytryptamine (2C) receptors. J Pharmacol Exp Ther 2000; 295: 1120-1126
• 51 Cesana R, Ceci A, Ciprandi C. et al. Mesulergine antagonism towards the fluoxetine anti-immobility effect in the forced swimming test in mice. Journal of Pharmacy and Pharmacology 1993; 45: 473-475
• 52 O’Leary OF, Bechtholt AJ, Crowley JJ. et al. Depletion of serotonin and catecholamines block the acute behavioral response to different classes of antidepressant drugs in the mouse tail suspension test. Psychopharmacology 2007; 192: 357-371
• 53 Page ME, Detke MJ, Dalvi A. et al. Serotonergic mediation of the effects of fluoxetine, but not desipramine, in the rat forced swimming test. Psychopharmacology 1999; 147: 162-167
• 54 An L, Zhang YZ, Yu NJ. et al. The total flavonoids extracted from Xiaobuxin-Tang up-regulate the decreased hippocampal neurogenesis and neurotrophic molecules expression in chronically stressed rats. Progress in NeuroPsychopharmacology and Biological Psychiatry 2008; 32: 1484-1490
• 55 Guan L-P, Liu B-Y. Antidepressant-like effects and mechanisms of flavonoids and related analogues. European Journal of Medicinal Chemistry 2016; 121: 47-57
• 56 Dixon Clarke SE, Ramsay RR. Dietary inhibitors of monoamine oxidase A. J Neural Transm 2011; 118: 1031-1041
• 57 Sakakibara H, Ishida K, Grundmann O. et al. Antidepressant effect of extracts from Ginkgo biloba leaves in behavioral models. Biol Pharm Bull 29: 1767-1770